is retatrutide a glp-1 The Science Behind Retatrutide: New Hope for Obesity and Diabetes – Prime Lab Peptides Retatrutide (Reta GLP-3) - 99%+

GLP-1- based treatments for T2DM, such as GLP-1 receptor agonists, dual and triple agonists that activate GLP-1R, GIPR, and glucagon receptors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have been reviewed here

How the FDA Approval Process Works For readers unfamiliar with FDA drug approval, here is how the remaining steps typically unfold: Step 1: Phase 3 Trial Completion The drug maker completes large-scale trials demonstrating safety and efficacy

Despite not being FDA-approved for weight loss, Trulicity is sometimes prescribed off-label for this purpose

In 2023, a daily oral orforglipron was found to be associated with weight reduction (9.4% to 14.7%) with similar adverse events when compared to subcutaneous GLP-1R agonists [40]